Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
65.63
+1.37 (+2.13%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
59
60
Next >
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
October 12, 2022
From
Alexion
Via
Business Wire
Illumina Inks AI Pact With AstraZeneca To Accelerate Drug Target Discovery
October 11, 2022
Via
Benzinga
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
October 11, 2022
Reuters US-China Chip War: KLA Relaxes Chip Supply To China
Via
Benzinga
AstraZeneca-Oxford University Partnered Nasal COVID-19 Vaccine Flunks Human Trial
October 11, 2022
AstraZeneca Plc (NASDAQ: AZN) and Oxford University scientists said that the initial testing of its nasal COVID-19 vaccine did not yield the desired protection.
Via
Benzinga
PhaseBio Might Have To Return Global Rights To Its Lead Program
September 28, 2022
Via
Benzinga
Japan Approves AstraZeneca's Two Treatments For Asthma, Rare Form Of Cancer
September 27, 2022
Via
Benzinga
Have $2,000? 2 Market Crash-Ready Stocks to Buy
October 09, 2022
These two big pharma stocks have what it takes to bounce back.
Via
The Motley Fool
2 Healthcare Stocks That Could Help Make You a Fortune
October 08, 2022
If given enough time, these two stocks can do the heavy lifting in building wealth for you.
Via
The Motley Fool
Is Illumina Still the Gamechanger in Genomics Sequencing?
October 04, 2022
Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused
Via
MarketBeat
Topics
Earnings
Economy
Lawsuit
Exposures
Financial
Legal
Supply Chain
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
October 03, 2022
Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio.
Via
Talk Markets
AstraZeneca's Asthma Treatment Scores European Approval
September 21, 2022
Via
Benzinga
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
September 20, 2022
Via
Benzinga
Will Chart Analysts Notice Bad Omen on AstraZeneca's Chart
October 03, 2022
If history is any guide, there may be trouble ahead for shares of AstraZeneca (NASDAQ:AZN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the...
Via
Benzinga
Why Is LogicBio (LOGC) Stock Up 600% Today?
October 03, 2022
LogicBio (LOGC) stock is seeing massive gains on Monday following news that AstraZeneca (AZN) subsidiary Alexion is acquiring the company.
Via
InvestorPlace
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
Vaccines that boost the body’s immune system against foreign proteins are different than those that are an inverse vaccine fighting an autoimmune disease.
Via
Benzinga
Why LogicBio Therapeutics Stock Is Soaring Today
October 03, 2022
LogicBio Therapeutics Inc (NASDAQ: LOGC) shares are trading higher Monday after the company announced it will be acquired by AstraZeneca PLC (NASDAQ: AZN) subsidiary Alexion for $2.07 per share.
Via
Benzinga
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
October 03, 2022
Via
Benzinga
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
October 03, 2022
From
Alexion
Via
Business Wire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
7 Large-Cap Stocks With Sustained Dividend Growth Potential
September 28, 2022
Large-cap stocks with dividend growth potential have robust cash flows and are likely to increase their dividends in the coming years.
Via
InvestorPlace
7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic’s Over’
September 27, 2022
Investors have seven widely-followed vaccine stocks to sell now, after the world decided the pandemic is over.
Via
InvestorPlace
US Stock Futures Rise Ahead Of Economic Reports, Fed Speakers; Crude Oil Rises 1%
September 27, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade on Tuesday after recording losses on Monday. The Dow Jones fell into a bear market on Monday, while the S&P 500 recorded a...
Via
Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
September 26, 2022
Via
Benzinga
European Stocks Are Left In Shambles From Russia-Ukraine War: It May Be Time To Buy These 2 High Yielders
September 25, 2022
As the SPDR Portfolio Europe ETF (ARCA: SPEU) is down roughly 32% year-to-date, it may be a prime moment to hunt for stocks that have become undervalued in the European stock market. The SPDR Portfolio...
Via
Benzinga
3 Medical Stocks Displaying Remarkable Relative Strength In 2022
September 24, 2022
3 medical stocks that displayed a substantial amount of relative strength year-to-date.
Via
Talk Markets
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
September 23, 2022
Though successful in early testing, it wasn't enough to win a Phase 3 study.
Via
Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
Via
Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
Via
Benzinga
Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis
September 16, 2022
From
Alexion
Via
Business Wire
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
59
60
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.